Enliven Therapeutics (ELVN) 8-K 23 Jun 23 Financial Statements and Supplementary Data Financial data

Cover Page

Cover Page	Jun. 23, 2023
Entity Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 23, 2023
Entity File Number	001-39247
Entity Registrant Name	Enliven Therapeutics, Inc.
Entity Central Index Key	0001672619
Entity Tax Identification Number	81-1523849
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6200 Lookout Road
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	720
Local Phone Number	647-8519
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ELVN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 75,536	$ 110,024
Prepaid expenses and other current assets	2,217	646
Total current assets	77,753	110,670
Property and equipment, net	890	492
Right-of-use asset	626	462
Deferred offering costs	3,975	1,651
Restricted cash	54	54
TOTAL ASSETS	83,298	113,329
Current liabilities:
Accounts payable, net	3,438	2,521
Accrued expenses and other current liabilities	6,277	3,232
Total current liabilities	9,715	5,753
LONG TERM LIABILITIES
Other non-current liabilities	659	714
Total liabilities	10,374	6,467
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS' EQUITY
Common stock $0.0001 par value; 26,264,364 shares authorized at December 31, 2022 and December 31, 2021; 3,570,019 and 3,435,014 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	1	1
Additional paid-in capital	6,038	2,314
Accumulated deficit	(82,864)	(45,202)
Total stockholders' deficit	(76,825)	(42,887)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT	83,298	113,329
Convertible Preferred Stock
LONG TERM LIABILITIES
Convertible preferred stock, $0.0001 par value; 61,730,064 shares authorized, issued and outstanding at December 31, 2022 and December 31, 2021, liquidation preference of $140,520 at December 31, 2022 and December 31, 2021	$ 149,749	$ 149,749

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	26,264,364	26,264,364
Common stock, shares issued	3,570,019	3,435,014
Common stock, shares outstanding	3,570,019	3,435,014
Convertible Preferred Stock
Statement [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	61,730,064	61,730,064
Preferred stock, shares issued	61,730,064	61,730,064
Preferred stock, shares outstanding	61,730,064	61,730,064
Preferred stock, liquidation preference, value	$ 140,520	$ 140,520

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 31,022	$ 20,474
General and administrative	7,769	4,288
Total operating expenses	38,791	24,762
Loss from operations	(38,791)	(24,762)
Other income (expense), net
Interest income	1,129	22
Total other income, net	1,129	22
Net loss and comprehensive loss	$ (37,662)	$ (24,740)
Net loss per share, basic	$ (12.05)	$ (10.73)
Net loss per share, diluted	$ (12.05)	$ (10.73)
Weighted-average shares outstanding, basic	3,124,274	2,306,110
Weighted-average shares outstanding, diluted	3,124,274	2,306,110

Statements of Convertible Prefe

Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement [Line Items]
Beginning balance	$ (42,887)	$ (20,304)
Exercise of common stock options	246	136
Vesting of restricted stock and stock options	287	97
Stock-based compensation	3,191	1,924
Net loss	(37,662)	(24,740)
Ending balance	(76,825)	(42,887)
Preferred Stock | Convertible Preferred Stock
Statement [Line Items]
Beginning balance	$ 149,749	$ 149,749
Beginning balance, shares	61,730,064	61,730,064
Ending balance	$ 149,749	$ 149,749
Ending balance, shares	61,730,064	61,730,064
Common stock
Statement [Line Items]
Beginning balance	$ 1	$ 1
Beginning balance, shares	3,435,014	3,257,927
Exercise of common stock options, shares	135,005	177,087
Ending balance	$ 1	$ 1
Ending balance, shares	3,570,019	3,435,014
Additional Paid-in Capital
Statement [Line Items]
Beginning balance	$ 2,314	$ 157
Exercise of common stock options	246	136
Vesting of restricted stock and stock options	287	97
Stock-based compensation	3,191	1,924
Ending balance	6,038	2,314
Accumulated Deficit
Statement [Line Items]
Beginning balance	(45,202)	(20,462)
Net loss	(37,662)	(24,740)
Ending balance	$ (82,864)	$ (45,202)

Statement of Cash Flows

Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (37,662)	$ (24,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	215	115
Stock-based compensation	3,191	1,924
Write-off of deferred IPO costs	1,741
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,590)	(563)
Right-of-use asset	4	133
Accounts payable	411	1,734
Accrued expenses and other liabilities	1,613	2,263
Net cash used in operating activities	(32,077)	(19,134)
Cash flows from investing activities:
Purchases of property and equipment	(612)	(191)
Net cash used in investing activities	(612)	(191)
Cash flows from financing activities:
Issuance of convertible preferred stock, net of issuance costs		(226)
Deferred issuance costs related to merger / initial public offering	(2,390)	(1,480)
Issuance of common stock	591	690
Net cash provided by financing activities	(1,799)	(1,016)
Net decrease in cash, cash equivalents and restricted cash	(34,488)	(20,341)
Cash, cash equivalents and restricted cash at the beginning of the period	110,078	130,419
Cash, cash equivalents and restricted cash at the end of the period	75,590	110,078
Components of cash, cash equivalents and restricted cash:
Cash and cash equivalents	75,536	110,024
Restricted cash	54	54
Total cash, cash equivalents and restricted cash	75,590	110,078
Supplemental disclosure of non-cash investing and financing activities:
Lease liability obtained in exchange for right of use asset	387	491
Accounts Payable
Supplemental disclosure of non-cash investing and financing activities:
Deferred issuance costs related to initial public offering included in accounts payable / liabilities		131
Deferred merger costs included in accounts payable / liabilities	656
Accrued Liabilities
Supplemental disclosure of non-cash investing and financing activities:
Deferred issuance costs related to initial public offering included in accounts payable / liabilities		$ 39
Deferred merger costs included in accounts payable / liabilities	$ 1,190

Organization, Description of Bu

Organization, Description of Business and Liquidity	12 Months Ended
	Dec. 31, 2022
Organization Description Of Business And Liquidity [Abstract]
Organization, Description of Business and Liquidity	1. Organization, Description of Business and Liquidity Business Enliven Therapeutics, Inc. (the Company) was incorporated in the State of Delaware on June 12, 2019 and is headquartered in Boulder, Colorado. The Company is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer not only live longer, but better. The Company aims to address emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Its discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. Since its inception, the Company has devoted substantially all of its efforts to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these activities. To date, the Company has funded its operations primarily through private placements of its convertible preferred stock. On October 13, 2022, the Company entered into an agreement and plan of merger (Merger Agreement) with Imara Inc. (Imara), a Delaware corporation and Iguana Merger Sub, Inc., a wholly-owned subsidiary of Imara (Merger Sub). Pursuant to the Merger Agreement, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the merger (the Merger). Immediately prior to the closing of the Merger, certain new and current investors subscribed for the purchase of an aggregate of approximately $164.5 million of common stock of Enliven (the Financing). On February 23, 2023, Enliven closed the Merger with Imara Inc. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc. Risks and uncertainties The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials, new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on third-party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, compliance with government regulations and the need to obtain additional financing. The Company continues to closely monitor macroeconomic and geopolitical developments, including the global COVID-19 Liquidity considerations In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional capital. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our capital requirements. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, that will occur. The Company has incurred significant losses and negative cash flows from operations since inception. As of December 31, 2022, the Company had an accumulated deficit of $82.9 million. The Company has incurred losses and negative cash flows from operations since inception, including net losses of $37.7 million and $24.7 million for the years ended December 31, 2022 and 2021, respectively. The Company expects that its operating losses and negative cash flows will continue for the foreseeable future as the Company continues to develop its product candidates. The Company currently expects that its cash and cash equivalents of $75.5 million as of December 31, 2022 will be sufficient to fund operating expenses and capital requirements for at least 12 months from the date the financial statements are issued. Merger Agreement and Exchange Ratio On October 13, 2022, the Company entered into the Merger Agreement with Imara, a Delaware corporation and Merger Sub. Pursuant to the Merger Agreement, among other matters, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Imara and the surviving corporation of the Merger. The Merger was intended to qualify for U.S. federal income tax purposes as a tax-free “reorganization” under the provisions of Section 368(a) of the Code and, in the event that former Enliven stockholders, including stockholders that participate in the Enliven pre-closing non-taxable Upon the closing of the Merger on February 23, 2023, (a) each outstanding share of Company common stock (including common stock issued upon the conversion of the Company’s preferred stock, and shares issued in the Financing) was converted into the right to receive a number of shares of Imara common stock (Imara Common Stock) (after giving effect to the 1-for-4 Immediately prior to the closing of the Merger, and in order to provide the Company with additional capital for its development programs, certain new and current investors purchased an aggregate of approximately $164.5 million of common stock of Enliven. The Merger and Financing were completed on February 23, 2023. The Merger has been accounted for as a reverse recapitalization under U.S. GAAP because the assets of Imara as of the effective date of the Merger are primarily cash and other non-operating of

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB). Use of estimates The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and stock-based Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations. Restricted cash The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets. Concentrations of credit risk and off-balance The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. Fair value measurements Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: • Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and • Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits. The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities. Deferred offering costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively. Property and equipment, net Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of three five years Impairment of long-lived assets The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements. Leases The Company elected to early adopt ASU No. 2016-02, right-of-use right-of-use non-lease Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other non-current Convertible preferred stock The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur. Research and development expenses The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and non-clinical The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and non-clinical Stock-based compensation The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur. The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: • Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock. • Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the mid-point • Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. • Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards. • Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero. The assumptions underlying these valuations represented the Company’s board and management’s best estimates, which Income taxes Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits. Net loss per share The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class Under the two-class Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive. Segments The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance. Comprehensive income (loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner Emerging growth company status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently issued accounting pronouncements adopted In December 2019, the FASB issued ASU 2019-12, 2019-12). 2019-12 adopted ASU 2019-12 January 1, 2022

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands): As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: US Treasury backed money market funds $ 74,523 $ 74,523 $ — $ — Total financial assets measured at fair value $ 74,523 $ 74,523 $ — $ — As of December 31, 2021 Total Level 1 Level 2 Level 3 Assets: US Treasury backed money market funds $ 106,768 $ 106,768 $ — $ — Total financial assets measured at fair value $ 106,768 $ 106,768 $ — $ — Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	4. Leases Facility lease In June 2020, the Company leased office and laboratory space under a sublease agreement for 6,782 square feet, which was set to expire on December 30, 2021. In March 2021, the Company amended its sublease agreement, increasing its leased space by 2,495 square feet to 9,277 square feet and monthly rent to $12,000. Upon the extension of the lease in March 2021, the lease was automatically extended to December 30, 2024. Additionally, in January 2022 the Company amended its sublease, which increased the leased space by an additional 8,893 square feet commencing on May 1, 2022, and the rental payments increased by an equally proportionate amount to reflect the increase in floor space. Further, in April 2022 the Company amended the sublease, which deferred the expansion for the additional space to July 1, 2022. The monthly rent is subject to annual increases through the lease term. The Company is required to pay base rent expense as well as its proportionate share of the facilities operating expenses. The non-lease non-lease The Company recognized rent expense under the facility sublease for the years ended December 31, 2022 and 2021 of $0.2 million. As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands): As of December 31, 2022 Year ending December 31, 2023 $ 329 2024 341 Total minimum lease payments 670 Less: amount representing interest 26 Present value of lease liabilities 644 Less: current portion of lease liabilities 323 Lease liabilities, noncurrent $ 321 During the years ended December 31, 2022 and 2021, the Company recognized $0.3 million and $0.2 million in variable lease costs, respectively.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following (dollars in thousands): Estimated Useful Life As of December 31, in Years 2022 2021 Laboratory equipment 5 $ 1,191 $ 614 Computer equipment 3 73 38 1,264 652 Less: accumulated depreciation (374 ) (160 ) Property and equipment, net $ 890 $ 492 Depreciation expense for the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): As of December 31, 2022 2021 Accrued employee compensation costs $ 2,130 $ 1,027 Accrued research and development costs 1,918 1,637 Accrued deferred offering costs 1,190 39 Lease liabilities 323 159 Accrued legal and professional fees 269 176 Other 447 194 Accrued expenses and other current liabilities $ 6,277 $ 3,232

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Lease commitments Litigation Indemnification agreements

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Common Stock	8. Common Stock As of December 31, 2022 and 2021, the Company’s Amended and Restated Certificate of Incorporation authorized the Company to issue 26,264,364 shares of $0.0001 par value common stock, of which 3,570,019 and 3,435,014 shares were issued and outstanding, respectively. As of December 31, 2022 and 2021, there were 252,652 and 703,092 shares which were subject to repurchase, respectively. The liability related to shares subject to repurchase totaled $0.6 million as of December 31, 2022 and 2021, of which $0.3 million and $0.4 million were recorded as other non-current Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company’s board of directors, if any, subject to the preferential dividend rights of any convertible preferred stock. No dividends have been declared or paid by the Company through December 31, 2022. In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any convertible preferred stock. The Company had the following shares of common stock reserved for future issuance: As of December 31, 2022 2021 Conversion of preferred stock 18,216,847 18,216,847 Issuance of common stock upon exercise of stock options 3,316,671 3,075,403 Options available for grant under stock plan 906,265 403,680 Total common stock reserved for future issuance 22,439,783 21,695,930

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Convertible Preferred Stock	9. Convertible Preferred Stock As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following: Aggregate Proceeds Net Shares Per Share Liquidation of Issuance Authorized Issued and Liquidation Amount Costs Shares Outstanding Preference (in thousands) (in thousands) Series Seed convertible preferred stock 14,507,038 14,507,038 $ 0.71 $ 10,300 $ 10,211 Series A convertible preferred stock 25,114,089 25,114,089 $ 1.80 45,300 45,170 Series B convertible preferred stock 22,108,937 22,108,937 $ 3.84 84,920 84,689 Total convertible preferred stock 61,730,064 61,730,064 $ 140,520 $ 140,070 No shares of convertible preferred stock were issued during the years ended December 31, 2022 and 2021. The Company’s convertible preferred stock have the following rights, preferences, privileges and restrictions: Voting as-converted Dividends Liquidation preference After payment of the liquidation preference to the holders of convertible preferred stock, the remaining assets of the Company shall be distributed ratably to the holders of common stock on a fully converted basis. Redemption Voluntary conversion non-assessable Automatic conversion then-effective

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Compensation Related Costs [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation Equity Incentive Plan non-statutory non-employees Awards granted under the 2019 Plan expire no later than 10 years from the date of grant. For incentive stock options and non-statutory Stock Option Repricing Effective August 9, 2022, the Company’s board of directors repriced certain previously granted and still outstanding vested and unvested stock option awards under the 2019 Plan. As a result, the exercise price for these awards was lowered to $2.48 per share, which was the fair value of the Company’s common stock on August 9, 2022. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 2,209,826 vested and unvested stock options outstanding as of August 9, 2022, with original exercise prices ranging from $4.68 to $7.56, were repriced. The repricing on August 9, 2022 resulted in incremental stock-based compensation expense of $1.0 million, of which $0.3 million related to vested stock option awards and was expensed on the repricing date, and $0.7 million related to unvested stock option awards is being amortized on a straight-line basis over the remaining weighted-average vesting period of those awards of approximately 2.9 years. The following table summarizes the stock plan activity: Available for Grant Stock Weighted- Weighted- Aggregate Outstanding - January 1, 2021 2,593,057 985,399 $ 1.12 9.47 $ 3,509 Options granted (2,189,377 ) 2,189,377 $ 4.71 9.38 Options exercised and vested — (99,373 ) $ 2.26 8.77 Outstanding - December 31, 2021 403,680 3,075,403 $ 3.64 9.11 $ 9,657 Increase in option pool 885,315 Options granted (391,653 ) 391,653 $ 5.66 9.38 Options exercised and vested — (141,462 ) $ 3.72 8.09 Options cancelled and forfeited 8,923 (8,923 ) $ 4.68 8.23 Outstanding - December 31, 2022 906,265 3,316,671 $ 2.20 8.26 $ 1,194 Exercisable - December 31, 2022 1,707,882 $ 1.85 8.00 Vested and expected to vest - December 31, 2022 3,316,671 $ 2.20 8.26 The total intrinsic value of exercised and vested incentive awards during the year ended December 31, 2022 was $0.1 million and is calculated on the difference between the exercise price and the fair value of the Company’s common stock as of the exercise date. The Company records stock-based compensation expense on a straight-line basis over the vesting period. As of December 31, 2022, total compensation cost not yet recognized related to unvested stock options was $7.7 million, which is expected to be recognized over a weighted-average period of 2.43 years. Restricted stock award activity —Upon formation of the Company in June 2019, the Company issued 3.0 million shares in restricted common stock to the founders of the Company at $0.0003 per share. 25% of the shares vested immediately upon issuance, with the remaining shares vesting evenly over 36 or 48 months. Vesting may be accelerated upon a change in control, as defined in the holder agreements. If the holders cease to have a business relationship with the Company, any unvested shares held by these individuals may be repurchased at their original purchase price. The unvested restricted stock is not considered outstanding for accounting purposes until the shares vest. As of December 31, 2022 and 2021, there were 41,499 and 438,045 shares subject to repurchase, respectively. Additionally, between 2019 and 2020, the Company issued a total of 197,262 shares of restricted stock to employees and consultants for aggregate consideration of $27,000. The purchase price of the restricted stock was the estimated fair value on the grant date. The restricted stock awards are subject to vesting over a period of four The following summarizes restricted stock activity: Number of Weighted- Unvested—December 31, 2020 160,935 $ 0.14 Granted — — Vested (63,032 ) 0.14 Forfeited — — Unvested—December 31, 2021 97,903 0.14 Granted — — Vested (47,446 ) 0.14 Forfeited — — Unvested—December 31, 2022 50,457 $ 0.14 The aggregate fair value of restricted stock that vested during the year ended December 31, 2022 was $0.1 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2022 was $0.14. Total intrinsic value of restricted stock as of December 31, 2022 was $0.2 million. As of December 31, 2022, total compensation cost not yet recognized related to unvested restricted stock was $4,000, which is expected to be recognized over a weighted-average period of 1.12 years. The aggregate fair value of restricted stock that vested during the year ended December 31, 2021 was $0.3 million. The weighted-average grant date fair value of restricted stock that vested during the year ended December 31, 2021 was $0.14. Total intrinsic value of restricted stock as of December 31, 2021 was $3.6 million. As of December 31, 2021, total compensation cost not yet recognized related to unvested restricted stock was $7,000, which is expected to be recognized over a weighted-average period of 2.04 years. Stock-based compensation expense Stock-based compensation expense is classified as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 1,893 $ 1,019 General and administrative 1,298 905 Total stock-based compensation expense $ 3,191 $ 1,924 The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used: Year Ended December 31, 2022 2021 Stock price $2.48 - $6.78 $5.69 - $7.18 Expected term (years) 5.8 - 6.3 Years 6 Years Expected volatility 80% 75% - 80% Risk-free interest rate 1.60% - 3.00% 1.00% - 1.40% Expected dividend yield — —

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The difference between the effective tax rate and the U.S. federal tax rate is as follows: Year Ended December 31, 2022 2021 Federal income tax (21.0 )% (21.0 )% State income tax, less federal benefits (6.7 )% (7.6 )% Permanent differences 1.5 % 1.7 % Change in valuation allowance 26.7 % 27.1 % Credits (0.5 )% (0.4 )% Other 0.0 % 0.2 % Effective tax rate 0.0 % 0.0 % Significant components of the Company’s deferred income taxes consist of the following (in thousands): As of December 31, 2022 2021 Deferred Tax Assets: Intangible asset basis differences $ 43 $ 47 Net operating loss carryforwards 12,894 8,918 Tax credit carryforwards 399 145 Capitalized research and development costs 5,422 — Other 1,017 530 Total deferred tax assets 19,775 9,640 Deferred Tax Liabilities: Fixed asset basis difference (49 ) (33 ) Goodwill differences (175 ) (129 ) Total deferred tax liabilities (224 ) (162 ) Valuation allowance (19,551 ) (9,478 ) Net deferred tax assets $ — $ — Realization of tax assets is dependent upon future earnings, the timing and amount of which are uncertain. Accordingly, the U.S. net deferred tax assets have been fully offset by a valuation allowance. The changes in the valuation allowance for the years ended December 31, 2022 and 2021 were $10.1 million and $6.7 million, respectively. As of December 31, 2022, the Company had federal net operating loss carryforwards of approximately $39.5 million, which has no expiration for federal tax purposes. As of December 31, 2022, the Company had California net operating loss carryforwards of approximately $65.8 million, which will begin to expire in 2039 for California tax purposes. At December 31, 2022, the Company also had Colorado net operating loss carryforwards of approximately $4,000, which will begin to expire in 2041 for Colorado tax purposes. Internal Revenue Code of 1986, as amended (IRC) Section 382 imposes limitations on the use of net operating loss carryforwards when the stock ownership of one or more 5% stockholders (stockholders owning more than 5% or more of the Company’s outstanding capital stock) has increased on a cumulative basis by more than 50 percentage points. There is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover. As of December 31, 2022, the Company has not completed an analysis whether an ownership change occurred under Section 382, which, if it did occur, could substantially limit its ability in the future to utilize its net operating loss and other tax carryforwards. As of December 31, 2022, the Company had Federal research and development credit carryforwards of approximately $0.4 million, which will begin to expire in 2041. The Company had California research and development carryforwards of $0.2 million, which will not expire. The Company adopted the provisions of FASB Accounting Standards Codification (ASC 740-10), 740-10 tax-related As of December 31, 2022 2021 Balance, beginning of the period $ 47 $ 7 Increase related to prior year positions 7 2 Increase related to current year positions 110 38 Balance, end of the period $ 164 $ 47 All tax returns will remain open for examination by the federal and state taxing authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards or research and development credits. On August 9, 2022 and August 16, 2022, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act and the Inflation Reduction Act (IRA), respectively, were signed into law. The CHIPS Act and IRA contain among other things, some income tax provisions that establish a corporate alternative minimum tax and provide tax incentives for semiconductor manufacturing and research. The Company has evaluated the current legislation and at this time, does not anticipate either to have a material impact on its financial statements. The Tax Cuts and Jobs Act (TCJA) included a change in the treatment of research and development (R&D) expenditures for tax purposes under Section 174. Effective for tax years beginning after December 31, 2021, specified R&D expenditures must undergo a 5-year 15-year 5-year

401(k) Savings Plan

401(k) Savings Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
401(k) Savings Plan	12. 401(k) Savings Plan The Company has a defined-contribution savings plan under IRC Section 401(k). The 401(k) Plan covers all employees who meet the defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. As of December 31, 2022 and 2021 the Company accrued no employee compensation costs for employer contributions payable to eligible employees.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts): Year Ended December 31, 2022 2021 Numerator: Net loss $ (37,662 ) $ (24,740 ) Denominator: Weighted-average common shares outstanding 3,548,829 3,335,786 Less: weighted-average unvested common stock issued upon early exercise of common stock options (194,966 ) (123,312 ) Less: weighted-average unvested restricted shares of common stock (229,589 ) (906,364 ) Weighted-average shares used to compute net loss per common share, basic and diluted 3,124,274 2,306,110 Net loss per share, basic and diluted $ (12.05 ) $ (10.73 ) The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, and common stock options, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: Year Ended December 31, 2022 2021 Convertible preferred stock (as converted) 18,216,847 18,216,847 Stock options outstanding 3,316,671 3,075,403 Unvested restricted stock 91,953 535,945 Total 21,625,471 21,828,195

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events The Company evaluated subsequent events from December 31, 2022, the date of these financial statements, through June 23, 2023, which represents the date the financial statements were issued for events requiring recording or disclosure in the financial statements for the year ended December 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the financial statements, except as described below. On February 23, 2023, Enliven closed the Merger with Imara Inc. Pursuant to the Merger Agreement, Merger Sub, a wholly owned subsidiary of Imara, merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Imara Inc. Immediately prior to the closing of the Merger, investors in the Financing purchased shares of Enliven’s common stock totaling $164.5 million. Following the closing of the Merger, Imara Inc. changed its corporate name to Enliven Therapeutics, Inc. In connection with the merger, a reverse stock split of Imara’s common stock was effectuated at a ratio of 1 to 4

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (US GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP, as found in the Accounting Standards Codification, (ASC), and Accounting Standards Update, (ASU), of the Financial Accounting Standards Board (FASB).
Use of estimates	Use of estimates The preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expense during the reporting period. The most significant estimates relate to the determination of fair value of the Company’s common stock and convertible preferred stock, determination of the fair value of the convertible preferred stock tranche liabilities and stock-based
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2022 and 2021, cash and cash equivalents consisted primarily of checking and money market funds composed of US government obligations.
Restricted cash	Restricted cash The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $54,000 as collateral for a sublease with the facility’s landlord. As of December 31, 2022 and 2021, $54,000 of restricted cash was recorded in restricted cash in the balance sheets.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance The Company maintains its cash accounts and money market fund that at times exceed insured limits. As of December 31, 2022 and 2021, the Company’s cash balances exceeded those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances.
Fair value measurements	Fair value measurements Financial assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the price the Company would receive to sell an investment in a timely transaction or pay to transfer a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: • Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2—Quoted prices in markets that are not considered to be active or financial instrument valuations for which all significant inputs are observable, either directly or indirectly; and • Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. The Company monitors the availability of inputs that are significant to the measurement of fair value to assess the appropriate categorization of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the Company’s policy is to recognize significant transfers between levels at the end of the reporting period. The significance of transfers between levels is evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets available for benefits. The Company’s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair value due to their short maturities.
Deferred offering costs	Deferred offering costs Deferred offering costs, consisting of legal, accounting and other fees and costs relating to the Company’s previously planned Initial Public Offering (IPO) and the Merger were capitalized and recorded on the balance sheets. During the year ended December 31, 2022, the Company expensed its previously capitalized deferred offering costs related to the previously planned IPO, which totaled $1.7 million, to general and administrative expenses, in the statement of operations and comprehensive loss. Deferred offering costs capitalized as of December 31, 2022 and 2021 were $4.0 million and $1.7 million, respectively.
Property and equipment, net	Property and equipment, net Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. The Company’s property and equipment consist of laboratory equipment and employee-related computers with estimated useful lives of three five years
Impairment of long-lived assets	Impairment of long-lived assets The Company evaluates long-lived assets, which consist of laboratory equipment and computers, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized in the Company’s financial statements.
Leases	Leases The Company elected to early adopt ASU No. 2016-02, right-of-use right-of-use non-lease Operating ROU assets are reflected in ROU assets. Operating lease liabilities are reflected in accrued expenses and other current liabilities, and other non-current
Convertible preferred stock	Convertible preferred stock The Company classifies convertible preferred stock outside of stockholders’ deficit on its balance sheet as the requirements of triggering a deemed liquidation event are not within the Company’s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (Note 9). The Company records the issuance of convertible preferred stock at the issuance price less related issuance costs and less any discount arising on allocation of proceeds to one or more derivative features. The Company has not adjusted the carrying values of the convertible preferred stock to its liquidation preference because of the uncertainty as to whether a deemed liquidation event may occur.
Research and development expenses	Research and development expenses The Company expenses research and development costs as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and non-clinical The Company estimates clinical and preclinical study expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In addition, clinical, preclinical, and non-clinical
Stock-based compensation	Stock-based compensation The Company measures and records the expense related to stock-based payment awards based on the estimated grant date fair value of those awards. The Company recognizes stock-based compensation expense over the requisite service period of the individual award, generally equal to the vesting period and uses the straight-line method to recognize stock-based compensation. The Company uses the Black-Scholes option pricing model to determine the fair value of the stock awards. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the variables used in the calculations, including the fair value of common stock, expected term, expected volatility of its common stock, risk-free interest rate and expected dividend yield. As the stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures, which the Company accounts for as they occur. The Company classifies equity-based compensation expense in the statement of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include: • Fair Value of Common Stock—As there has been no public market for the Company’s common stock to date, the estimated fair value of the Company’s common stock has been determined by the board of directors as of the date of each option grant with input from management, considering the most recently available third-party valuation of common stock. • Expected Term—The expected term represents the period that the Company’s options are expected to be outstanding and is determined using the simplified method (based on the mid-point • Expected Volatility—The expected stock price volatilities are estimated based on the historical and implied volatilities of comparable publicly traded companies as the Company does not have sufficient history of trading its common stock. • Risk-Free Interest Rate—The risk-free interest rates are based on U.S. Treasury yields in effect at the grant date for notes with comparable terms as the awards. • Expected Dividend Yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on the Company’s common stock. Therefore, the Company used an expected dividend of zero. The assumptions underlying these valuations represented the Company’s board and management’s best estimates, which
Income taxes	Income taxes Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of its provision for income taxes. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Net loss per share	Net loss per share The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class Under the two-class Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options and unvested early exercised common stock and unvested restricted common stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share were the same, as any additional share equivalents would be anti-dilutive.
Segments	Segments The Company operates in one segment and, accordingly, no segment disclosures have been presented herein. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for allocating and evaluating financial performance.
Comprehensive income (loss)	Comprehensive income (loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner
Emerging growth company status	Emerging growth company status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently issued accounting pronouncements adopted	Recently issued accounting pronouncements adopted In December 2019, the FASB issued ASU 2019-12, 2019-12). 2019-12 adopted ASU 2019-12 January 1, 2022

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value on a Recurring Basis	The following tables set forth the fair value of the Company’s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands): As of December 31, 2022 Total Level 1 Level 2 Level 3 Assets: US Treasury backed money market funds $ 74,523 $ 74,523 $ — $ — Total financial assets measured at fair value $ 74,523 $ 74,523 $ — $ — As of December 31, 2021 Total Level 1 Level 2 Level 3 Assets: US Treasury backed money market funds $ 106,768 $ 106,768 $ — $ — Total financial assets measured at fair value $ 106,768 $ 106,768 $ — $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Summary of Future Minimum Lease Payments Under Operating Sublease	As of December 31, 2022 the future minimum lease payments under the facilities operating sublease were as follows (in thousands): As of December 31, 2022 Year ending December 31, 2023 $ 329 2024 341 Total minimum lease payments 670 Less: amount representing interest 26 Present value of lease liabilities 644 Less: current portion of lease liabilities 323 Lease liabilities, noncurrent $ 321

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (dollars in thousands): Estimated Useful Life As of December 31, in Years 2022 2021 Laboratory equipment 5 $ 1,191 $ 614 Computer equipment 3 73 38 1,264 652 Less: accumulated depreciation (374 ) (160 ) Property and equipment, net $ 890 $ 492

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Summary Of Accrued Expenses And Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): As of December 31, 2022 2021 Accrued employee compensation costs $ 2,130 $ 1,027 Accrued research and development costs 1,918 1,637 Accrued deferred offering costs 1,190 39 Lease liabilities 323 159 Accrued legal and professional fees 269 176 Other 447 194 Accrued expenses and other current liabilities $ 6,277 $ 3,232

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Following Shares of Common Stock Reserved for Future Issuance	The Company had the following shares of common stock reserved for future issuance: As of December 31, 2022 2021 Conversion of preferred stock 18,216,847 18,216,847 Issuance of common stock upon exercise of stock options 3,316,671 3,075,403 Options available for grant under stock plan 906,265 403,680 Total common stock reserved for future issuance 22,439,783 21,695,930

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Convertible Preferred Stock	As of December 31, 2022 and 2021, the Company’s Amended and Restated Articles of Incorporation designated and authorized the Company to issue up to 61,730,064 shares of convertible preferred stock which consisted of the following: Aggregate Proceeds Net Shares Per Share Liquidation of Issuance Authorized Issued and Liquidation Amount Costs Shares Outstanding Preference (in thousands) (in thousands) Series Seed convertible preferred stock 14,507,038 14,507,038 $ 0.71 $ 10,300 $ 10,211 Series A convertible preferred stock 25,114,089 25,114,089 $ 1.80 45,300 45,170 Series B convertible preferred stock 22,108,937 22,108,937 $ 3.84 84,920 84,689 Total convertible preferred stock 61,730,064 61,730,064 $ 140,520 $ 140,070

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Compensation Related Costs [Abstract]
Summary of Stock Plan Activity	The following table summarizes the stock plan activity: Available for Grant Stock Weighted- Weighted- Aggregate Outstanding - January 1, 2021 2,593,057 985,399 $ 1.12 9.47 $ 3,509 Options granted (2,189,377 ) 2,189,377 $ 4.71 9.38 Options exercised and vested — (99,373 ) $ 2.26 8.77 Outstanding - December 31, 2021 403,680 3,075,403 $ 3.64 9.11 $ 9,657 Increase in option pool 885,315 Options granted (391,653 ) 391,653 $ 5.66 9.38 Options exercised and vested — (141,462 ) $ 3.72 8.09 Options cancelled and forfeited 8,923 (8,923 ) $ 4.68 8.23 Outstanding - December 31, 2022 906,265 3,316,671 $ 2.20 8.26 $ 1,194 Exercisable - December 31, 2022 1,707,882 $ 1.85 8.00 Vested and expected to vest - December 31, 2022 3,316,671 $ 2.20 8.26
Summary of Restricted Stock Activity	The following summarizes restricted stock activity: Number of Weighted- Unvested—December 31, 2020 160,935 $ 0.14 Granted — — Vested (63,032 ) 0.14 Forfeited — — Unvested—December 31, 2021 97,903 0.14 Granted — — Vested (47,446 ) 0.14 Forfeited — — Unvested—December 31, 2022 50,457 $ 0.14
Summary of Stock-Based Compensation Expense	Stock-based compensation expense is classified as follows (in thousands): Year Ended December 31, 2022 2021 Research and development $ 1,893 $ 1,019 General and administrative 1,298 905 Total stock-based compensation expense $ 3,191 $ 1,924
Summary of Stock-Based Compensation Fair Value Assumptions	The fair value of each stock option grant is estimated on the date of grant using a Black-Scholes model. The following summarizes the inputs used: Year Ended December 31, 2022 2021 Stock price $2.48 - $6.78 $5.69 - $7.18 Expected term (years) 5.8 - 6.3 Years 6 Years Expected volatility 80% 75% - 80% Risk-free interest rate 1.60% - 3.00% 1.00% - 1.40% Expected dividend yield — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Summary of Effective Tax Rate and The U.S. Federal Tax Rate	The difference between the effective tax rate and the U.S. federal tax rate is as follows: Year Ended December 31, 2022 2021 Federal income tax (21.0 )% (21.0 )% State income tax, less federal benefits (6.7 )% (7.6 )% Permanent differences 1.5 % 1.7 % Change in valuation allowance 26.7 % 27.1 % Credits (0.5 )% (0.4 )% Other 0.0 % 0.2 % Effective tax rate 0.0 % 0.0 %
Summary of Company's Deferred Income Taxes	Significant components of the Company’s deferred income taxes consist of the following (in thousands): As of December 31, 2022 2021 Deferred Tax Assets: Intangible asset basis differences $ 43 $ 47 Net operating loss carryforwards 12,894 8,918 Tax credit carryforwards 399 145 Capitalized research and development costs 5,422 — Other 1,017 530 Total deferred tax assets 19,775 9,640 Deferred Tax Liabilities: Fixed asset basis difference (49 ) (33 ) Goodwill differences (175 ) (129 ) Total deferred tax liabilities (224 ) (162 ) Valuation allowance (19,551 ) (9,478 ) Net deferred tax assets $ — $ —
Summary of Company's Unrecognized Tax Benefits	The following table summarizes the changes to the Company’s unrecognized tax benefits (in thousands): As of December 31, 2022 2021 Balance, beginning of the period $ 47 $ 7 Increase related to prior year positions 7 2 Increase related to current year positions 110 38 Balance, end of the period $ 164 $ 47

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Common Share	Basic and diluted net loss per common share were calculated as follows (in thousands, except share and per share amounts): Year Ended December 31, 2022 2021 Numerator: Net loss $ (37,662 ) $ (24,740 ) Denominator: Weighted-average common shares outstanding 3,548,829 3,335,786 Less: weighted-average unvested common stock issued upon early exercise of common stock options (194,966 ) (123,312 ) Less: weighted-average unvested restricted shares of common stock (229,589 ) (906,364 ) Weighted-average shares used to compute net loss per common share, basic and diluted 3,124,274 2,306,110 Net loss per share, basic and diluted $ (12.05 ) $ (10.73 )
Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share	The following potential dilutive securities, presented on an as converted basis, were excluded from the calculation of net loss per share due to their anti-dilutive effect: Year Ended December 31, 2022 2021 Convertible preferred stock (as converted) 18,216,847 18,216,847 Stock options outstanding 3,316,671 3,075,403 Unvested restricted stock 91,953 535,945 Total 21,625,471 21,828,195

Organization, Description of _2

Organization, Description of Business and Liquidity - Additional Information (Details) $ in Thousands			12 Months Ended
	Jun. 23, 2023	Feb. 23, 2023 USD ($) DIRECTOR	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Organization, Description of Business and Liquidity [Line Items]
Entity incorporation date	Jun. 12, 2019
Reverse stock split		1-for-4
Majority number of initial members of board of directors | DIRECTOR		8
Common Stock Value		$ 164,500	$ 1	$ 1
Accumulated deficit			(82,864)	(45,202)
Net loss			(37,662)	(24,740)
Cash and cash equivalents			$ 75,536	$ 110,024

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)
Summary of Significant Accounting Policies [LineItems]
Restricted cash	$ 54,000	$ 54,000
Restricted cash collateral of sublease	54,000
Losses recognized by uninsured balances	0
Deferred offering costs capitalized	$ 4,000,000	$ 1,700,000
Expected dividend yield	0%
Number of operating segments | Segment	1
Adoption of accounting standards update [true false]	true
Accounting standards update, adoption date	Jan. 01, 2022
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2019-12 [Member]
Accounting standards update, immaterial effect [true false]	true
General and administrative expenses | IPO
Summary of Significant Accounting Policies [LineItems]
Deferred offering costs capitalized	$ 1,700,000
Minimum
Summary of Significant Accounting Policies [LineItems]
Property and equipment estimated useful lives	3 years
Maximum
Summary of Significant Accounting Policies [LineItems]
Property and equipment estimated useful lives	5 years

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets:
Total financial assets measured at fair value	$ 74,523	$ 106,768
U.S. Treasury Backed Money Market Funds
Assets:
Total financial assets measured at fair value	74,523	106,768
Level 1
Assets:
Total financial assets measured at fair value	74,523	106,768
Level 1 | U.S. Treasury Backed Money Market Funds
Assets:
Total financial assets measured at fair value	74,523	106,768
Level 2
Assets:
Total financial assets measured at fair value	0	0
Level 2 | U.S. Treasury Backed Money Market Funds
Assets:
Total financial assets measured at fair value	0	0
Level 3
Assets:
Total financial assets measured at fair value	0	0
Level 3 | U.S. Treasury Backed Money Market Funds
Assets:
Total financial assets measured at fair value	$ 0	$ 0

Leases - Additional Information

Leases - Additional Information (Details)	1 Months Ended				12 Months Ended
	Apr. 30, 2022	Jan. 31, 2022 ft²	Mar. 31, 2021 USD ($)	Jun. 30, 2020 ft²	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 01, 2021 ft²	Feb. 28, 2021 ft²
Leases [Abstract]
Area of leased office and laboratory space | ft²				6,782
Lease expiration date				Dec. 30, 2021
Square feet of office space leased | ft²		8,893					9,277	2,495
Lease and rental expense			$ 12,000		$ 200,000	$ 200,000
Lease renewal term for office space extended date			Dec. 30, 2024
Lease commencement date	Jul. 01, 2022	May 01, 2022
Incremental borrowing rate of right of used assets and lease liabilities					4%
Remaining lease liability					$ 600,000	500,000
Remaining operating lease right of use asset					600,000	500,000
Variable lease costs					$ 300,000	$ 200,000

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under Operating Sublease (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 329
2024	341
Total minimum lease payments	670
Less: amount representing interest	26
Present value of lease liabilities	644
Less: current portion of lease liabilities	323
Lease liabilities, noncurrent	$ 321

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,264	$ 652
Less: accumulated depreciation	(374)	(160)
Property and equipment, net	890	492
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,191	614
Property and equipment estimated useful lives	5
Computer equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 73	$ 38
Property and equipment estimated useful lives	3

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.2	$ 0.1

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued employee compensation costs	$ 2,130	$ 1,027
Accrued research and development costs	1,918	1,637
Accrued deferred offering costs	1,190	39
Lease liabilities	323	159
Accrued legal and professional fees	269	176
Other	447	194
Accrued expenses and other current liabilities	$ 6,277	$ 3,232

Common Stock - Additional Infor

Common Stock - Additional Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Vote $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized | shares	26,264,364	26,264,364
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Common stock, shares issued | shares	3,570,019	3,435,014
Common stock, shares outstanding | shares	3,570,019	3,435,014
Shares subject to repurchase | shares	252,652	703,092
Liability related to shares subject to repurchase | $	$ 600	$ 600
Number of vote by common stock holders | Vote	1
Long-term liabilities
Class of Stock [Line Items]
Liability related to shares subject to repurchase | $	$ 300	$ 400
Dividend Declared
Class of Stock [Line Items]
Dividends | $	0
Dividend Paid
Class of Stock [Line Items]
Dividends | $	$ 0

Common Stock - Following Shares

Common Stock - Following Shares of Common Stock Reserved for Future Issuance (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Conversion of preferred stock	18,216,847	18,216,847
Issuance of common stock upon exercise of stock options	3,316,671	3,075,403
Options available for grant under stock plans	906,265	403,680	2,593,057
Common stock reserved for future issuance	22,439,783	21,695,930

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized	61,730,064	61,730,064
Preferred stock, shares issued	61,730,064	61,730,064
Preferred stock, par value	$ 0.0001	$ 0.0001
Sale of stock, consideration received per transaction	$ 75
Convertible Preferred Stock | Merger Agreement
Class of Stock [Line Items]
Preferred stock, shares issued	0	0
Series Seed Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized	14,507,038	14,507,038
Preferred stock dividend rate	$ 0.0426
Preferred stock, par value	$ 0.71
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized	25,114,089	25,114,089
Preferred stock dividend rate	$ 0.108226
Preferred stock, par value	$ 1.803768
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized	22,108,937	22,108,937
Preferred stock dividend rate	$ 0.2305
Preferred stock, par value	$ 3.84098

Convertible Preferred Stock - S

Convertible Preferred Stock - Schedule of Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Proceeds Net of Issuance Costs		$ (226)
Series Seed Convertible Preferred Stock
Class of Stock [Line Items]
Authorized Shares	14,507,038	14,507,038
Shares Issued and Outstanding	14,507,038	14,507,038
Per Share Liquidation Preference	$ 0.71	$ 0.71
Aggregate Liquidation Amount	$ 10,300	$ 10,300
Proceeds Net of Issuance Costs	$ 10,211	$ 10,211
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Authorized Shares	25,114,089	25,114,089
Shares Issued and Outstanding	25,114,089	25,114,089
Per Share Liquidation Preference	$ 1.8	$ 1.8
Aggregate Liquidation Amount	$ 45,300	$ 45,300
Proceeds Net of Issuance Costs	$ 45,170	$ 45,170
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Authorized Shares	22,108,937	22,108,937
Shares Issued and Outstanding	22,108,937	22,108,937
Per Share Liquidation Preference	$ 3.84	$ 3.84
Aggregate Liquidation Amount	$ 84,920	$ 84,920
Proceeds Net of Issuance Costs	$ 84,689	$ 84,689
Total Convertible Preferred Stock
Class of Stock [Line Items]
Authorized Shares	61,730,064	61,730,064
Shares Issued and Outstanding	61,730,064	61,730,064
Aggregate Liquidation Amount	$ 140,520	$ 140,520
Proceeds Net of Issuance Costs	$ 140,070	$ 140,070

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)		1 Months Ended				12 Months Ended		19 Months Ended
	Aug. 09, 2022	Dec. 31, 2020	Aug. 31, 2020	Apr. 30, 2020	Jun. 30, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share based compensation expense						$ 3,191,000	$ 1,924,000
Incremental stock-based compensation expense						3,191,000	1,924,000
Total compensation cost not yet recognized related to unvested stock options						$ 7,700,000
Expected to be recognized over a weighted-average period						2 years 5 months 4 days
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised And Vested Intrinsic Value						$ 100,000
Share-Based Payment Award, Options, Outstanding, Intrinsic Value		$ 3,509,000				1,194,000	9,657,000	$ 3,509,000
Stock Option Repricing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share based compensation expense	$ 1,000,000
Minimum exercise price for repriced options	$ 4.68
Maximum exercise price for repriced options	$ 7.56
Repricing vested and unvested stock options outstanding	2,209,826
Incremental stock-based compensation expense	$ 1,000,000
Incremental stock compensation expense for option repricing for vested stock options.	300,000
Incremental stock compensation expense for option repricing for unvested stock options	$ 700,000
Remaining weighted-average vesting period	2 years 10 months 24 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Payment Award Options Vested in Period Fair Value						100,000	300,000
Total compensation cost not yet recognized related to unvested stock options						$ 4,000	$ 7,000
Expected to be recognized over a weighted-average period						1 year 1 month 13 days	2 years 14 days
Shares subject to repurchase						41,499	438,045
Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value						$ 0.14	$ 0.14
Share-Based Payment Award, Options, Outstanding, Intrinsic Value						$ 200,000	$ 3,600,000
Restricted Stock | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issued shares in restricted common stock to its founders					3,000,000
Issued shares in restricted common stock to its founders , per share					$ 0.0003
Restricted Stock | Enliven Inc. | Vested Upon Issuance
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested immediately upon issuance					25%
Restricted Stock | Employees and Consultants | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock shares issued								197,262
Restricted stock shares issued value								$ 27,000
Maximum | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period						5 years
Maximum | Restricted Stock | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares vesting period					48 months
Minimum | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period						4 years
Minimum | Restricted Stock | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining shares vesting period					36 months
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized			4,681,244
Number of additional shares authorized			885,315
Sharebased Compensation Arrangement By Sharebased Payment Award Exercise Price Of Common Stock Percent						100%
2019 Equity Incentive Plan | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized		3,795,929		2,584,138				3,795,929
Number of additional shares authorized		1,211,791		2,210,062
2019 Equity Incentive Plan | Stock Option Repricing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Excercise price for repriced options	$ 2.48
2019 Equity Incentive Plan | Maximum | Enliven Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized									374,076

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Plan Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Compensation Related Costs [Abstract]
Available for Grant, Beginning Balance	403,680	2,593,057
Available for Grant, Options granted	(391,653)	(2,189,377)
Available for Grant, Increase in option pool	885,315
Available for Grant, Options cancelled and forfeited	8,923
Available for Grant, Ending Balance	906,265	403,680	2,593,057
Stock Options Outstanding, Beginning Balance	3,075,403	985,399
Stock Options Outstanding, Options granted	391,653	2,189,377
Stock Options Outstanding, Options cancelled and forfeited	(8,923)
Stock Options Outstanding, Options exercised and vested	(141,462)	(99,373)
Stock Options Outstanding, Exercisable	1,707,882
Stock Options Outstanding, Vested and expected to vest	3,316,671
Stock Options Outstanding, Ending Balance	3,316,671	3,075,403	985,399
Weighted-Average Exercise Price, Beginning Balance	$ 3.64	$ 1.12
Weighted-Average Exercise Price, Options granted	5.66	4.71
Weighted-Average Exercise Price, Options exercised and vested	3.72	2.26
Weighted- Average Exercise Price, Options cancelled and forfeited	4.68
Weighted-Average Exercise Price, Ending Balance	2.2	$ 3.64	$ 1.12
Weighted- Average Exercise Price, Exercisable	1.85
Weighted- Average Exercise Price, Vested and expected to vest	$ 2.2
Weighted- Average Contractual Term, Outstanding	8 years 3 months 3 days	9 years 1 month 9 days	9 years 5 months 19 days
Weighted- Average Contractual Term, Options granted	9 years 4 months 17 days	9 years 4 months 17 days
Weighted- Average Contractual Term, Options exercised and vested	8 years 1 month 2 days	8 years 9 months 7 days
Weighted- Average Contractual Term, Options cancelled and forfeited	8 years 2 months 23 days
Weighted- Average Contractual Term, Exercisable	8 years
Weighted- Average Contractual Term, Vested and expected to vest	8 years 3 months 3 days
Aggregate Intrinsic Value, Options cancelled and forfeited
Aggregate Intrinsic Value, Beginning Balance	$ 9,657	$ 3,509
Aggregate Intrinsic Value, Options granted
Aggregate Intrinsic Value, Options exercised and vested
Aggregate Intrinsic Value, Ending Balance	1,194	$ 9,657	$ 3,509
Aggregate Intrinsic Value, Vested and expected to vest
Aggregate Intrinsic Value, Exercisable

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested, Beginning Balance	97,903	160,935
Number of Shares, Vested	(47,446)	(63,032)
Number of Shares, Unvested, Ending Balance	50,457	97,903
Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance	$ 0.14	$ 0.14
Weighted-Average Grant Date Fair Value, Vested	0.14	0.14
Weighted-Average Grant Date Fair Value, Unvested, Ending Balance	$ 0.14	$ 0.14

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 3,191	$ 1,924
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Allocated share based compensation expense	1,893	1,019
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 1,298	$ 905

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Stock-Based Compensation Fair Value Assumptions (Details) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (years)		6 years
Expected volatility	80%
Risk-free interest rate, minimum	1.60%	1%
Risk-free interest rate, maximum	3%	1.40%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Price	$ 2.48	$ 5.69
Expected term (years)	5 years 9 months 18 days
Expected volatility		75%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Price	$ 6.78	$ 7.18
Expected term (years)	6 years 3 months 18 days
Expected volatility		80%

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective Tax Rate and The U.S. Federal Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Federal income tax	(21.00%)	(21.00%)
State income tax, less federal benefits	(6.70%)	(7.60%)
Permanent differences	1.50%	1.70%
Change in valuation allowance	26.70%	27.10%
Credits	(0.50%)	(0.40%)
Other	0%	0.20%
Effective tax rate	0%	0%

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Components of Deferred Tax Assets and Liabilities [Abstract]
Intangible asset basis differences	$ 43	$ 47
Net operating loss carryforwards	12,894	8,918
Tax credit carryforwards	399	145
Capitalized research and development costs	5,422
Other	1,017	530
Total deferred tax assets	19,775	9,640
Deferred Tax Liabilities:
Fixed asset basis difference	(49)	(33)
Goodwill differences	(175)	(129)
Total deferred tax liabilities	(224)	(162)
Valuation allowance	(19,551)	(9,478)
Net deferred tax assets

Income Taxes - Summary of Com_2

Income Taxes - Summary of Company's Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Uncertainties [Abstract]
Balance, beginning of the period	$ 47	$ 7
Increase related to prior year positions	7	2
Increase related to current year positions	110	38
Balance, end of the period	$ 164	$ 47

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Line Items]
Changes in the valuation allowance	$ 10,100,000	$ 6,700,000
Minimum change in percentage of stock holding	50%
Income tax examination, description	All tax returns will remain open for examination by the federal and state taxing authorities for three and four years
Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Income tax penalties expense	$ 0	$ 0
Unrecognized tax benefits recognized, would affect the effective tax rate	$ 200,000
Minimum
Income Tax Disclosure [Line Items]
Percentage of stock holding	5%
Post Tax Year 2021 | The Tax Cuts And Jobs Act
Income Tax Disclosure [Line Items]
Amortization period of specified research and development expenses domestic spend	5 years
Amortization period of specified research and development expenses foreign spend	15 years
Tax Year 2021 and Prior
Income Tax Disclosure [Line Items]
Amortization period of specified research and development expenses	5 years
Domestic Tax Authority | Internal Revenue Service (IRS) | Not Expirable
Income Tax Disclosure [Line Items]
Operating loss carryforwards	$ 39,500,000
Domestic Tax Authority | Internal Revenue Service (IRS) | Tax Year 2041 | Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Tax credit carryforward	$ 400,000
State and Local Jurisdiction | Internal Revenue Service (IRS) | Tax Year 2041 | Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Tax credit carryforward expiration year	2041
State and Local Jurisdiction | California Franchise Tax Board | Not Expirable | Research Tax Credit Carryforward
Income Tax Disclosure [Line Items]
Tax credit carryforward	$ 200,000
State and Local Jurisdiction | California Franchise Tax Board | Tax Year 2039
Income Tax Disclosure [Line Items]
Operating loss carryforwards	$ 65,800,000
Operating loss carryforwards expiration year	2039
State and Local Jurisdiction | Colorado Tax Authority | Tax Year 2041
Income Tax Disclosure [Line Items]
Operating loss carryforwards	$ 4,000
Operating loss carryforwards expiration year	2041

401(k) Savings Plan - Additiona

401(k) Savings Plan - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
401(k) Savings Plan liability	$ 0	$ 0

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss	$ (37,662)	$ (24,740)
Denominator:
Weighted-Average Common Shares Outstanding	3,548,829	3,335,786
Less: weighted-average unvested common stock issued upon early exercise of common stock options	(194,966)	(123,312)
Less: weighted-average unvested restricted shares of common stock	(229,589)	(906,364)
Weighted-average shares outstanding, basic	3,124,274	2,306,110
Weighted-average shares outstanding, diluted	3,124,274	2,306,110
Net loss per share, basic	$ (12.05)	$ (10.73)
Net loss per share, diluted	$ (12.05)	$ (10.73)

Net Loss Per Share - Anti Dilut

Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share Basic [Line Items]
Convertible preferred stock (as converted)	21,625,471	21,828,195
Convertible Preferred Stock (as converted)
Earnings Per Share Basic [Line Items]
Convertible preferred stock (as converted)	18,216,847	18,216,847
Stock Options Outstanding
Earnings Per Share Basic [Line Items]
Convertible preferred stock (as converted)	3,316,671	3,075,403
Unvested Restricted Stock
Earnings Per Share Basic [Line Items]
Convertible preferred stock (as converted)	91,953	535,945

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	Feb. 23, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Common stock value	$ 164,500	$ 1	$ 1
Reverse stock split	1-for-4
Business acquisition, exchange ratio	0.2951%